HK1135030A1 - Composition useful for the treatment of type 2 diabetes - Google Patents

Composition useful for the treatment of type 2 diabetes

Info

Publication number
HK1135030A1
HK1135030A1 HK10101743.6A HK10101743A HK1135030A1 HK 1135030 A1 HK1135030 A1 HK 1135030A1 HK 10101743 A HK10101743 A HK 10101743A HK 1135030 A1 HK1135030 A1 HK 1135030A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
treatment
type
composition useful
canitine
Prior art date
Application number
HK10101743.6A
Other languages
English (en)
Inventor
Franco Gaetani
Ashraf Virmani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of HK1135030A1 publication Critical patent/HK1135030A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK10101743.6A 2007-02-27 2010-02-18 Composition useful for the treatment of type 2 diabetes HK1135030A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103137 2007-02-27
PCT/EP2007/062545 WO2008104239A1 (fr) 2007-02-27 2007-11-20 Composition à utiliser pour le traitement du diabète de type 2

Publications (1)

Publication Number Publication Date
HK1135030A1 true HK1135030A1 (en) 2010-05-28

Family

ID=38093451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10101743.6A HK1135030A1 (en) 2007-02-27 2010-02-18 Composition useful for the treatment of type 2 diabetes

Country Status (17)

Country Link
US (2) US20100029759A1 (fr)
EP (1) EP2124925B1 (fr)
JP (2) JP5697337B2 (fr)
KR (1) KR101699430B1 (fr)
CN (1) CN101616665B (fr)
AU (1) AU2007348123B2 (fr)
BR (1) BRPI0721333A8 (fr)
CA (1) CA2678746C (fr)
EA (1) EA016855B1 (fr)
ES (1) ES2676529T3 (fr)
HK (1) HK1135030A1 (fr)
IL (1) IL200192A (fr)
MX (1) MX2009008873A (fr)
PL (1) PL2124925T3 (fr)
PT (1) PT2124925T (fr)
SG (1) SG177993A1 (fr)
WO (1) WO2008104239A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101699430B1 (ko) * 2007-02-27 2017-01-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. ２형 당뇨의 치료에 유용한 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
US20020061301A1 (en) * 1998-05-15 2002-05-23 Olga Bandman Human carbohydrate metabolism enzymes
HUP0201597A3 (en) * 1999-06-08 2003-04-28 Sigma Tau Ind Farmaceutiche S Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
US20080102138A1 (en) * 2006-06-21 2008-05-01 Bieley Harlan C Replacement of Vitamins, Minerals and Neurotransmitter Losses from Tobacco Smoking
KR101699430B1 (ko) * 2007-02-27 2017-01-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. ２형 당뇨의 치료에 유용한 조성물

Also Published As

Publication number Publication date
IL200192A0 (en) 2010-04-15
KR101699430B1 (ko) 2017-01-24
EA200970798A1 (ru) 2010-04-30
IL200192A (en) 2015-06-30
AU2007348123A1 (en) 2008-09-04
CN101616665A (zh) 2009-12-30
PT2124925T (pt) 2018-07-12
EP2124925A1 (fr) 2009-12-02
MX2009008873A (es) 2009-08-28
EA016855B1 (ru) 2012-08-30
US20150045424A1 (en) 2015-02-12
CA2678746A1 (fr) 2008-09-04
BRPI0721333A2 (pt) 2014-02-25
JP5697337B2 (ja) 2015-04-08
SG177993A1 (en) 2012-02-28
CN101616665B (zh) 2013-03-27
PL2124925T3 (pl) 2018-09-28
EP2124925B1 (fr) 2018-06-27
CA2678746C (fr) 2018-05-01
JP2014040442A (ja) 2014-03-06
KR20090115939A (ko) 2009-11-10
WO2008104239A1 (fr) 2008-09-04
ES2676529T3 (es) 2018-07-20
BRPI0721333A8 (pt) 2017-12-26
JP2010519333A (ja) 2010-06-03
AU2007348123B2 (en) 2013-01-17
US20100029759A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
MY148723A (en) Use of pinolenic acid for the treatment of obesity
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
TW200716628A (en) Novel compounds
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL201479A (en) Use of tapentadol for the preparation of pain medication
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
SI1861080T1 (sl) Idebenon za zdravljenje miĺ iäśnih distrofij, njegovo pripravo in farmacevtska uporaba
MX2009011900A (es) Curacion de herida diabetica.
ZA201003794B (en) Novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation
TNSN08506A1 (en) Substituted carboxamides
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
HK1135030A1 (en) Composition useful for the treatment of type 2 diabetes
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
SI1937245T1 (sl) Spojina uporabna za preprečevanje in zdravljenjeleve ventrikularne hipertofije pri dializiranih pacientih
ZA201005394B (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
IL206381A0 (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative
MY154883A (en) A combination composition
TW200640457A (en) Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
RO122835B1 (ro) Utilizarea dietilaminei ca analgezic în preparate farmaceutice

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231118